B-type Natriuretic Peptide + Adrenomedullin Peptide Stack

This synergistic stack integrates B-type Natriuretic Peptide (BNP), renowned for its cardiovascular and natriuretic properties, with Adrenomedullin, a potent vasoactive peptide. Both peptides play crucial roles in the cardiovascular system, interacting with various signaling pathways that regulate vascular tone and fluid homeostasis. BNP serves as a pivotal biomarker in heart failure diagnostics, while Adrenomedullin is being investigated for its potential in prognostic assessments. Research indicates that the independent vasodilatory systems associated with these peptides can be measured alongside heart failure prognostic panels, suggesting their combined use may enhance the understanding of cardiovascular disease mechanisms.

B-type Natriuretic Peptide (BNP) is a 32-amino-acid cardiac hormone (molecular weight ~3464 g/mol) secreted predominantly by ventricular cardiomyocytes in response to myocardial wall stress due to volume or pressure overload. BNP is integral not only as a diagnostic biomarker for heart failure, with assays like BNP/NT-proBNP, but also forms the foundation for therapeutic agents such as nesiritide. Initially discovered in porcine brain tissue, BNP's historical nomenclature reflects its origins.

Mechanism: BNP exerts its effects primarily by binding to natriuretic peptide receptor A (NPR-A), triggering the activation of guanylyl cyclase and subsequently increasing cGMP levels. This cascade activates protein kinase G (PKG), leading to vasodilation through the reduction of intracellular calcium in smooth muscle cells, promoting natriuresis, and inhibiting the renin-angiotensin-aldosterone system (RAAS). BNP also plays a role in mitigating cardiac fibrosis and sympathetic nervous system activity via cGMP-mediated pathways. The peptide is synthesized as preproBNP, which is processed through several forms before being secreted as BNP and NT-proBNP, the latter having a longer half-life and renal clearance.

Adrenomedullin is a 52-amino-acid vasodilatory peptide (molecular weight ~6028 g/mol) that was first isolated from human pheochromocytoma tissue. It is widely expressed within the cardiovascular system, as well as in the lungs, kidneys, and adrenal glands, showcasing its extensive physiological roles. Adrenomedullin is recognized for its vasodilatory, natriuretic, and cardioprotective properties, and is currently under investigation as a biomarker (MR-proADM) for sepsis and heart failure prognosis, though it lacks an approved therapeutic application.

Mechanism: The peptide signals through the calcitonin receptor-like receptor (CLR) in conjunction with receptor activity-modifying proteins 2 or 3 (RAMP2/RAMP3), leading to the formation of AM1 and AM2 receptors. This interaction activates Gs-coupled adenylyl cyclase, which elevates cAMP levels, subsequently activating protein kinase A (PKA) and promoting endothelial nitric oxide synthase (eNOS) phosphorylation, resulting in nitric oxide (NO) release. The ensuing vasodilation decreases systemic vascular resistance and blood pressure, while also enhancing renal blood flow and inhibiting aldosterone secretion. Adrenomedullin further exhibits anti-apoptotic, anti-inflammatory, and anti-fibrotic effects in cardiomyocytes and vascular cells. The peptide is derived from a 185-amino-acid precursor, with a plasma half-life of approximately 22 minutes, while the mid-regional fragment of proadrenomedullin (MR-proADM) serves as a more stable biomarker.